Some restomods try to walk the line between nostalgia and performance. This one doesn’t bother with half-measures. Finished ...

Approval based on results of landmark Phase 3 C-POST trial that show Libtayo is first immunotherapy to significantly improve disease-free survival in CSCC in the adjuvant setting, reducing the risk of ...